Skip to content

Professor Hannah Cock

Professor of Epilepsy and Medical Education
Professor Cock is course director for MBBS, a consultant neurologist (epilepsy), and research active
Molecular & Clinical Sciences Research Institute

Professor Cock has roles in education, research and clinical practice. She is a consultant neurologist in the Atkinson Morley Regional Epilepsy Network, based at St George's hospital. In addition to her educational roles, she has research interests in status epilepticus (prolonged uncontrolled seizures), Sudden Unexpected Death in Epilepsy, the treatment of drug-resistant epilepsy, and improving services and care for people with epilepsy. 

Professor Cock is currently course director for MBBS (medicine), and Vice-Chair of London Medicine London Medicine – London Higher

Biography

Professor Cock qualified from the University of London in 1989, and also completed her post-graduate and research training in and around London. She Joined St George's in 2003 as a Consultant Neurologist at Atkinson Morley Regional Neuroscience Centre, St Georges University Hospitals NHS Foundation Trust and Senior Lecturer, and is now Professor of Epilepsy and Medical Education jointly affiliated to the Institute of Medical & Biomedical Education, and the Institute of Molecular and Clinical Sciences (Clinical Neurosciences Group) at St George’s, University of London. 

Throughout her career she has been active in clinical practice, research and education. Her clinical practice encompasses the diagnosis and management of all aspects of epilepsy, within a now thriving regional service including a full range of diagnostic and treatment services. Prior to her postgraduate neurology training, she was awarded a Medical Research Council scholarship for her MD research project looking at cellular mechanisms involved in Mitochondrial diseases. Having subsequently developed a clinical interest in epilepsy during her training, she was appointed as clinical lecturer to Professor Simon Shorvon at the Institute of Neurology, London. Work funded by a post-doctoral Welcome Advanced Fellowship exploring the role of mitochondrial dysfunction in seizure-related brain damage contributed to her receiving the Millenium Young Investigators award in 1999 from the International League Against Epilepsy (UK).  Her primary research interest has been in status epilepticus (prolonged uncontrolled seizures), moving initially from laboratory based work into clinical trials. Education has also always been a core part of her portfolio, including a number of local, national and international roles in both undergraduate and post-graduate medical education.  She completed a Professional Accreditation in Teaching and Learning in Higher education at the Institute of Education, London in 2000, and is a Fellow of the Higher Education Academy. 

Her only son (2006-2016) had profound multiple learning disabilities and complex health needs including severe epilepsy. This has inevitably informed her academic and clinical practice, enabled her to also speak from a patient/carer perspective about disability and epilepsy, as well as inspiring her to develop a massive online course "organ donation: the essentials for healthcare professionals" in collaboration with NHS Blood and Transplant after his death. 

Awards and scholarships

  • 2021, St George's University of London, Excellence in Education Award for supportive leadership of the MBBS team
  • 2019, Honorary Membership of the Moldovan Neurological Society
  • 2019 European Academy of Neurology Service award (for outstanding contribution to neurology education)
  • 2019 St Georges University Hospitals NHS Foundation Trust,  Excellence in Education Awards, Most Inspiring Lecturer
  • 2018 Fellow of the European Academy of Neurology
  • 2001 Wellcome Trust Advanced Training Fellowship
  • 999 International League Against Epilepsy British Branch, Young Scientific Investigators Prize
  • 1996 Royal Society of Medicine, Section of Neurology, Gordon Holmes Registrar's Prize
  • 1994 Medical Research Council Clinical Training Fellowship
  • 1989 Douglas Cree Prize for Medicine
  • 1985 Medical Research Council Scholarship for BSc (Physiology)

External Appointments

  • International League Against Epilepsy, E-learning task force (2017- 
  • Clinical Advisor, Epilepsy Action UK (2007-)
  • Scientific Advisory Committee member, Epilepsy Research UK (2018 - )
  • NHS England Specialised Adult neuroscience Transformation Programme, Epilepsy Clinical Working Group (2018-19)
  • UK NIHR Clinical Research Network, London South Epilepsy Lead (2015-19)
  • Clinical Lead, ebrain project ebrainjnc.com (2010-2019)
  • Chair, Education Committee & Board Member, European Academy of Neurology (2014-18)
  • NHS England Invited expert, Policy Working Group for Everolimus for Partial-onset seizures in Tuberous Sclerosis Complex (2017-18). 
  • Epilepsy Advocacy Europe, Executive Member (2013-14)
  • ILAE Classification Taskforce, Status Epilepticus (2009-2014)
  • European Neurological Society, Board member (2006-2014), including as Teaching course director (2012-14)
  • Chair Interventions & therapeutics Clinical Study Group, UK Epilepsy Research Network (2010-2014)
  • Editorial Boards European Journal of Neurology (2014 - ), Epilepsia (2009-2012), Journal of Neurology (2007-2011)

Membership/Affiliations:

Fellow of the European Academy of Neurology, Royal College of Physicians London, Higher Education Academy and European academy of Neurology. Member of the American Epilepsy Societu, Royal Society of Medicine, International League Against Epilepsy, Association of British Neurologists,  American Academy of Neurology, UK Register Expert Witnesses

Professor Cock is affiliated with the Clinical Neurosciences Center in the Molecular and Clinical Sciences Research Institute. On her appointment to St George's led a research group who moved with her, working in experimental models (laboratory based) of epilepsy, focusing on the consequences and treatment of status epilepticus (prolonged uncontrolled seizures), and novel treatment approaches for difficult to treat epilepsy. Following the birth of her son with complex needs (b2006-d2016), she elected to close the laboratory and focus on more clinical and collaborative projects.

Professor Cock was a collaborator on several pilot non-epileptic seizure trials with a team in Sheffield, and subsequently the site principal investigator for CODES (cognitive behavioural therapy for dissociative seizures), led by colleagues at King's College London and Sheffield. With the local team, she has also validated and developed screening tools for anxiety and depression in epilepsy, now routinely used in the epilepsy service at St George’s, with further work ongoing in this area. 

Following a research sabbatical in 2009, Professor Cock initially lead, and subsequently remained a core part of the team team delivering the Established Status Epilepticus Treatment Trial. This is a double blind randomised controlled trial of valproate, levetiracetam and phenytoin in status epilepticus which has not responded to initial benzodiazepines, funded by a $21.4million grant from the USA NIH NINDS (Ref U01NS088034) in September 2014. Recruitment took place between November 2015-January 2019, and the results published in the New England Journal of Medicine and Lancet Journals amongst others. 

Professor Cock has also been site Principal Investigator for numerous academic and industry sponsored studies, as well as UK Chief investigator for one. Of particular note are: 

  • Person Centred Risk communication: what works best for people with epilepsy and their clinicians, an NIHR funded Project undertaken during 2020-22
  • SANAD2 study, a clinical trial to determine the most effective and cost-effective treatment for newly diagnosed epilepsy
  • EMPIRE Antiepileptic drug (AED) management in pregnancy: an evaluation of effectiveness, cost effectiveness, and acceptability of dose adjustment strategies (EMPiRE). Participating in this study supported the development of a now well established joint epilepsy-maternal medicine pathway and service for women with epilepsy managed at St George's. 
  • EXIST3, a study of Everolimus, a potentially disease modifying treatment, and GWPCARE6 A Randomized Controlled Trial of Cannabidiol, both in drug resistant epilepsy due to tuberous sclerosis  complex. This is a genetic disorder causing epilepsy, learning disability and other problems, Professor is the adult epilepsy lead for the supra-regional tuberous sclerosis service, and has been able to use her experience from these trials to set up regional pathways to support delivery of novel treatments for rare and complex epilepsies.

Original Papers

  1. Wu JY, Cock HR, Devinsky O, Joshi C, Miller I, Roberts CM, Sanchez-carpintero R, Checketts D, Sahebkar F. Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: post hoc analysis of randomized controlled phase 3 trial GWPCARE6. Epilepsia (2022) 63:1189-99 doi: 10.1111/epi.17199
  2. Sathe AG, Underwood E, Coles LD, Elm J, Silbergleit R, Chamberlain JM, Kapur J, Cock HR, Fountain NB, Shinnar S, Lowenstein DH, Rosenthal ES, Conwit RA, Bleck TP, Clloyd JC. Patterns of benzodiazepine underdosing in the Established Status Epilepticus Treatment Trial. Epilepsia 2021 (online first) https://doi.org/10.1111/epi.16825
  3. Sathe AG, Mishra U, Ivaturi V, Brundage R, Cloyd JC, Elm JJ, Chamberlain JM, Silbergleit R, Kapur J, Lowenstein DH, Shinnar S, Cock HR, Fountain N, Babcock L, Coles LD. Early exposure of fosphenytoin, levetiracetam and valproic acid after high dose intravenous administration in young children with benzodiazepine-refractory status epilepticus. Journal of Clinical Pharmacology (2021) 61 (6); 763-768 https://doi.org/10.1002/jcph.1801
  4. Kinney M, Chester V, Tromans S, Regi A, Angus-Leppan H, Bagary M, Cock HR, Devapriam J, Hassiotis A, Mula M, Reuber M, Ring H, Ashok R, Scheepers M, Shankar R. Epilepsy, anti-seizure medication, intellectual disability and challenging behaviour – Everyone’s business, no one’s priority. Seizure (2020) 81:111-116 https://doi.org/10.1016/j.seizure.2020.07.018
  5. Goldstein LH, Robinson, Emily EJ, Mellers JDC, Stone J, Carson A, Reuber M, Medford N, McCrone P, Murray J, Richards MP, Pilecka I, Eastwood C, Moore M, Mosweu I, Perdue I, Landau WS, Chalder T on behalf of the CODES study group (Cock HR and 167 others). Cognitive behavioural therapy for adults with dissociative seizures (CODES): a pragmatic, multicentre, randomised controlled trial. Lancet Psychiatry (2020) 7; 491-505 https://doi.org/10.1016/S2215-0366(20)30128-0
  6. Sathe AG, Elme JJ, Cloyd JC, Chamberlain JM, Silbergleit R, Kapur J, Cock HR, Fountain NB, Shinnar S, Lowenstein DH, Conwit RA, Bleck TP, Coles LD. The Association of Patient Weight and Dose of Fosphenytoin, Levetiracetam and Valproic acid with Treatment Success in Status Epilepticus. Epilepsia (2020) online first http://dx.doi.org/10.1111/epi.16534
  7. Chamberlain JM, Kapur J, Shinnar S, Elm J, Holsti M, Babcock L, Rogers A, Barsan W, Cloyd J, Lowenstein D, Bleck TP, Conwit R, Meinzer C, Cock H, Fountain NB, Underwood E, Conner JT, Silbergleit R, for the Neurological Emergencies Treatment Trials and the Pediatric Emergency Care Applied Research Network Investigators. Efficacy of levetiracetam, fosphenytoin and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive adaptive, randomised controlled trial. The Lancet (2020) 395:1217-24 org/10.1016/S0140-6736(20)30611-5
  8. Angus-Leppan, H; Moghim M, Cock H, Kinton, L, Synnott-Wells M, Shankar R. Valproate risk form – surveying 215 clinicians involving 4775 encounters, Acta Neurological Scandinavia Published online 2020 doi:1111/ane.13231
  9. Kapur J, Elm J, Chamberlain JM, Barsan W, Clloyd J, Lowenstein D, Shinnar S, Conwit R, Meinzer C, Cock H, Fountain N, Connor JT, Silbergleit R. Randomized trial of three anticonvulsant medications for status epilepticus. New England Journal of Medicine (2019) 318(22); 2103-2013 doi:10.1056/NEJMoa1905795
  10. Sathe AG, Tillman H, Coles LD, Elm JJ, Silbergleit R, Chamberlain J, Kapur J, Cock HR, Fountain NB, Shinnar S, Lowenstein DL, Conwit RA, Bleck TP, Cloyd JC. Underdosing of benzodiazepines in patients with status epilepticus enrolled in an established status epilepticus treatment trial. Academic Emergency Medicine (2019) 26; 940-43. doi/full/10.1111/acem.13811
  11. Cock HR, Coles LD, Elm J, Silbergleit R, Chamberlain JM, Cloyd JC, Fountain N, Shinnar S, Lowenstein D, Conwit R, Bleck TP, Kapur J. Lessons from the Established Status Epilepticus Treatment Trial, Epilepsy & Behaviour (2019) 101(B):106296 org/10.1016/j.yebeh.2019.04.049
  12. Martos Martinez-Caja A, De Herdt V, Boon P, Brandl U, Cock H, Parra J, Perucca E, Thadani V, Moons CPH. Seizure-alerting behaviour in dogs owned by people experiencing seizures. Epilepsy & Behavior (2019) 94; 104-11 org/10.1016/j.yebeh.2019.02.001
  13. Popkirov S, Nicholson TR, Bloem BR, Cock HR, Derry CP, Duncan R, Dworetzky BA, Edwards MJ, Espay AJ, Hallett M, Lang AE, Leach JP, Lehn A, McGonigal A, Morgante F, Perez DL, Reuber M, Richardson M, Smith P, Stamelou M, Tijssen MAJ, Tinazzi M, Carson AJ, Stone J. Hiding in plain sight – functional neurological disorders in the news. Journal of Neuropsychiatry & Clinical Neurosciences (2019 in press) doi:/10.1176/appi.neuropsych.19010025
  14. Theochari E, Cock H, Lozsadi L, Galtrey C, Arevalo J, Mula M. Brivaracetam in adults with drug resistant epilepsy and psychiatric comorbidities. Epilepsy and Behaviour (2019); 90:129-131 doi:/10.1016/j.yebeh.2018.11.032
  15. Cock HR Learning from an exceptional boy Practical Neurology (2018); 18:170-71 10.1136/practneurol-2017-001853
  16. Zis P, Macerollo A, Sauerbier A, Papp V, Klingelhoefer L, Cock HR. Subspecialty preferences among neurologists of the future. European Journal of Neurology (2018); 35(3), 597-601. doi:10.1111/ene.13526
  17. Ridsdale L, Wojewodka G, Robinson E, Landau S, Noble A, Taylor S, Richardson M, Baker G, Goldstein LH, SMILE Team (Cock HR, one of SMILE team detailed separately at end of manuscript). Characteristics associated with quality of life among people with drug resistant epilepsy. J Neurology (2017); 264(6):1174-1184 doi:10.1007/s00415-017-8512-1
  18. Knight J, Stroud L, Geyton T, Stead A, Cock HR. Medical student perceptions of clinical neurosurgery teaching in an undergraduate medical school curriculum. British Journal of Neurosurgery (2017); 31(6):727-730 doi DOI: 1080/02688697.2017.1335856
  19. Gur-Ozman S, Mula M, Agrawal N, Cock HR, Lozsadi D, Von Oertzen T. The role of depression and side effects of antiepileptic drugs on injuries in patients with epilepsy. European Journal Of Neurology (2017); 24(9)1135-39 DOI:1111/ene.13346/full
  20. Mula M, Von Oertzen TJ, Cock HR, Yogarajah M, Loszadi D, Agrawal N. Fatigue during treatment with antiepileptic drugs: a levetiracetam specific adverse event? Epilepsy and behaviour (2017); 72:17-21 DOI: 1016/j.yebeh.2017.04.030
  21. Caruana-Galizia E, Isaacs JD, Cock HR Non-Hyperammonaemic Valproate encephalopathy after 20 years of treatment. Epilepsy and Behaviour Case Reports (2017); 8:9-11 DOI:1016/j.ebcr.2017.04.002
  22. Gur-Ozmen S, Leibetseder A, Cock HR, Agrawal N, von Oertzen TJ; Screening of anxiety and quality of life in people with epilepsy. Seizure (2017); 45:107-113 Doi: 1016/j.seizure.2016.11.026
  23. Agrawal N, Bird JS, Von Oertzen TJ, Cock HR, Mitchell AJ, Mula M. Depression correlates with quality of life in people with epilepsy independent of measures used. Epilepsy and behaviour (2016); 62:246-50 DOI:1016/j.yebeh.2016.07.020
  24. Thompson AGB, Cock HR. Successful treatment of super-refractory tonic status epilepticus with rufinamide: first clinical report. Seizure (2016) ; 39:1-4 DOI: 1016/j.seizure.2016.04.003
  25. Mula M, von Oertzen TJ, Cock HR, Lozsadi DA, Agrawal N. Clinical correlates of memory complaints during antiepileptic drug treatment in adults with epilepsy. Acta Neurologica Scandinavia (2016); 134 (5):368-73 DOI: 1111/ane.12553
  26. Mula M, Danqueh-Boateng D, Cock HR, Khan U, Lozsadi D, Nirmalananthan N. Different attachment styles correlate with mood disorders in adults with epilepsy or migraine Epilepsy & Behaviour (2015); 54:110-114 DOI: 1016/j.yebeh.2015.11.023
  27. Trinka E, Cock HR, Hesdorrfer D, Rossetti AO, Scheffer IE, Shinnar S, Shorvon S, Lowenstein D. A Definition and Classification of Status Epilepticus – Report of the Task Force on Classification of Status Epilepticus Epilepsia (2015); 56(10);1515-1523 DOI:1111/epi.13121
  28. Mula M, Agrawal N, Mustafa Z, Mohanalingham, Cock HR, Lozsadi DA, von Oertzen TJ. Self-reported aggressiveness during treatment with levetiracetam correlates with depression Epilepsy and Behaviour (2015);45;64-67 DOI:1016/j.yebeh.2015.03.018
  29. Drinovac M, Wagner H, Agrawal N, Cock HR, Mitchell AJ, von Oertzen T. Screening for depression in epilepsy: A model for an enhanced screening tool. Epilepsy and Behaviour (2015); 44; 67-72 DOI:1016/j.yebeh.2014.12.014
  30. Mitchel AJ, Iannou N, Rampling JM, von Oertzen T, Cock HR, Agrawal A. Which Symptoms are Indicative of Depression in Epilepsy Settings? An Analysis of the Diagnostic Significance of Somatic and Non-Somatic Symptoms Journal of Affective Disorders. Journal of Affective Disorders (2013) 250(3):861- 867 DOI:1016/j.jad.2013.03.020
  31. Bleck T, Cock H, Chamberlain J, Cloyd J, Connor J, Elm J, Fountain N, Jones E, Lowenstein D, Shinnar S, Silbergleit R, Treiman D, Trinka E, Kapur J. The Established Status Epilepticus Treatment Trial 2013 Epilepsia (2013); 54(Suppl1) 89-92 DOI:1111/epi.12288
  32. Mayor R, Brown, RJ., Cock H., House A, Howlett S, Smith P, & Reuber M. (2013). A feasibility study of a brief psycho-educational intervention for psychogenic nonepileptic seizures. Seizure, 22(9), 760-765 DOI:1016/j.seizure.2013.06.008
  33. Mayor R, Brown RJ, Cock H, House A, Howlett S, Singhal S, Smith P, Reuber R. Short-term outcome of psychogenic nonepileptic seizures after communication of the diagnosis. Epilepsy and Behaviour (2012); 25(5) 686-71 DOI:1016/j.yebeh.2012.09.033
  34. Understanding patient perceptions following a psycho-educational intervention for psychogenic non-epileptic seizures. Baxter S, Mayor R, Baird W, Brown R, Cock H, Howlett S, House A, Messina J, Smith P, Reuber M. Epilepsy and behaviour (2012; 24(3) 487-93 DOI:1016/j.yebeh.2011.12.002
  35. Rampling JR, Mitchell AJ, Von Oertzen J, Docker J, Jackson J, Cock HR, Agrawal N. Screening for Depression in Epilepsy Clinics. A Comparison of Conventional and Visual-Analogue Methods. Epilepsia (2012) 53(10):1713-21 2012 DOI:1111/j.1528-1167.2012.03571.x
  36. Hamil N E, Cock HR, Walker MC Acute down-regulation of adenosine A1 receptor activity in status epilepticus. Epilepsia 2012; 53(1):177-88 DOI:1111/j.1528-1167.2011.03340.x
  37. Cock HR, on behalf of ESETT group. Established Status Epilepticus Treatment Trial. Epilepsia (2011) 52(suppl8): 50-52 DOI:1111/j.1528-1167.2011.03237.x
  38. Hall-Patch L, Brown R, House A, Howlett S, Kemp S, Lawton G, Mayor R, Smith P, Reuber M and NEST Collaborators Group (Including Cock HR) Acceptability and effectiveness of a strategy for the communication of the diagnosis of psychogenic non-epileptic seizures Epilepsia (2010) 51(1):70-78 DOI: 1111/j.1528-1167.2009.02099.x
  39. Gaynor, D, Cock HR, Agrawal, N. Psychological treatments for functional non-epileptic attacks: a systematic review. Acta Neuropsychiatrica (2009), ­21(4):158-68 DOI:1111/j.1601-5215.2009.00376.x
  40. Pomeroy V M, Hiscok H, Cock H, Tallis R C. Impact of carbamazepine on postural control in older adults: an exploratory study. Physiotherapy (2008) 94:230-235 DOI:1016/j.physio.2008.03.004
  41. Gibbs, J E, Cock HR. Administration of Levetiracetam after prolonged status epilepticus does not protect from mitochondrial dysfunction in a rodent model Epilepsy research (2007) 73(2):208-212 DOI:1016/j.eplepsyres.2006.09.005
  42. Sleven H J, Gibbs J E, Cock HR. The anti-oxidant N-acetyl-L-cysteine does not prevent hippocampal glutathione loss or mitochondrial dysfunction associated with status epilepticus Epilepsy Research (2006) 69(2):165-69 DOI:1016/j.eplepsyres.2006.01.006
  43. Nilsen K E, Kelso A R C, Cock HR. Antiepileptic effect of gap junction blockers in a rat model of refractory focal cortical epilepsy Epilepsia (2006) 47(7): 1169-1175 DOI:1111/j.1528-1167.2006.00540.x
  44. Pearce K M, Cock HR. An audit of electroencephalography requests: use and misuse Seizure (2006) 15(3):184-189 DOI:1016/j.seizure.2006.01.003
  45. Gibbs J E, Walker M C, Cock HR. Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus Epilepsia (2006) 47(3):1-10 DOI:1111/j.1528-1167.2006.00454.x
  46. Sleven H, Gibbs J E, Heales S, Thom M, Cock HR. Depletion of reduced glutathione precedes inactivation of mitochondrial enzymes following limbic status epilepticus in the rat hippocampus. Neurochemistry International (2006) 48(2):75-82 DOI:1016/j.neuint.2005.10.002
  47. Nilsen K E, Walker M C, Cock HR. Characterisation of the tetanus toxin model of refractory focal neocortical epilepsy in the rat. Epilepsia (2005) 46(2):1-9 DOI:1111/j.0013-9580.2005.26004.x
  48. Fisher A, Cock HR, Patsalos P N, Wang X, Walker M C. Synergistic interaction between topiramate and the NMDA antagonist budipine in a model of self sustaining status epilepticus. Epilepsia (2004) 45(11):1300-07 DOI:1111/j.0013-9580.2004.26404.x
  49. Depondt C, Cock HR, Healy D G, Burley M W, Weinshenker D, Wood N W, Goldstein D B, Sisodiya, S M. The -1021C->T DBH gene variant is not associated with epilepsy or antiepileptic drug response. Neurology (2004) 63(8):1497-99 DOI:​1212/​01.​WNL.​0000142092.​16719.​AD
  50. Cock HR, Tong X, Hargreaves I P, Heales S J R, Clark J B, Patsalos P N, Thom M, Groves M, Schapira A H V, Shorvon S D, Walker MC. Mitochondrial dysfunction associated with neuronal death following status epilepticus in rat. Epilepsy Research (2002) 48(3):157-168 DOI: 1016/S0920-1211(01)00334-5
  51. Cock HR, Schapira AHV. A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus. QJM, (2002) 95:1-7 DOI: 1093/qjmed/95.4.225
  52. Cock HR, Cooper J M, Schapira A H V. Functional consequences of the 3460-bp mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Journal of Neurological Sciences (1999) 165(1):10-17 DOI: 1016/S0022-510X(99)00088-X
  53. Cock HR, Tabrizi S J, Cooper J M, Schapira A H V. The influence of nuclear background on the biochemical expression of 3460 Leber’s hereditary optic neuropathy. Annals of Neurology (1998) 44:187-93 DOI:1002/ana.410440208
  54. Cock HR, Mandler R, Ahmed W, Schapira A H V. Neuromyelitis optica (Devic's syndrome): no association with the primary mitochondrial DNA mutations found in Leber’s hereditary optic neuropathy. Journal of Neurology, Neurosurgery and Psychiatry (1997) 62:85-87 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC486701/
  55. Cock HR, Cooper J M, Schapira A H V. The 14484 ND6 mitochondrial DNA mutation in Leber’s hereditary optic neuropathy does not affect fibroblast complex I activity. American Journal of Human Genetics (1995) 57:1501-1502 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1801418/
  56. Sheldon C D, Probert C S, Cock HR, King K, Rampton S D,Barnes N C, Mayberry J F. Incidence of abdominal tuberculosis in Bangladeshi migrants in east London Tubercle and Lung Disease (1993) 74(1):12-15 DOI:1016/0962-8479(93)90061-2
  57. Sheldon C, King K, Cock HR, Wilkinson P, Barnes N. Notification of Tuberculosis: How many are never reported? Thorax (1992) 47:1015 – 1018 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1021092/

Chapters, editorials, letters and reviews

  1. Management of Status Epilepticus: a narrative review; Migdady I, Rosenthal E, Cock HR Anaesthesia (2022) 77 (Suppl 1):78-91 doi:10.1111/anae.15606
  2. Jenkins P, Cock HR. Post-traumatic Epilepsy: Epidemiology, Definition and Terminology. Chapter 2, p 29-46 in Post-Traumatic Epilepsy, Ed Marco Mula, Cambridge University Press 2021 (ISBN 9781108494229 (hardback) ISBN 9781108644594 (ebook)
  3. Sutton F, Barca D, Komoltsev I, Craiu D, Guekht A, von Oertzen T, Cock HR. Testing blood and CSF in people with epilepsy: a practical guide. Epileptic Disorders (2020) 22(4):381-96 doi 10.1684/epd.2020.1191
  4. Crawshaw A, Cock HR. Medical management of status epilepticus: emergency room to intensive care unit. Seizure (2020) 75:145-152 org/10.1016/j.seizure.2019.10.006
  5. Cross H, Cock HR. A perspective on cannabinoids for treating epilepsy: do they really change the landscape? Neuropharmacology (2019) epub ahead of print doi: 10.1016/j.neuropharm.2019.107861
  6. Morrish P, Duncan S, Cock HR. Epilepsy deaths. Learning from health service delivery and trying to reduce risk, Epilepsy and Behavior (2020) 103(B) 106473: 1-8 doi:10.1016/j.yebeh.2019.106473
  7. Mayer J, Kipps CM, Cock HR. Implementing clinical guidelines: how to do it. Practical neurology (2019) 19:529-535 doi:10.1136/ practneurol-2017-001814
  8. Watkins LV, Cock HR Angus-Leppan H, Shankar R. Valproate and the Pregnancy Prevention Programme: exceptional circumstances. British Journal of General Practice (2019) 69(681): 166-167 org/10.3399/bjgp19X701897
  9. Watkins L, Cock H, Angus-Leppan H, Morley K, Wilcock M, Shankar R. Valproate MHRA guidance: limitations and opportunities. Frontiers in Neurology (2019); 10 (139):1-4 doi:3389/fneur.2019.00139
  10. Theocharia E, Cock HR. Bone health and epilepsy, Chapter 3 in The comorbidities of epilepsy, Ed Mula, M, Elsevier Publishing (2019) p 27-49. https://doi.org/10.1016/B978-0-12-814877-8.00003-9 Watkins L, Cock HR, Angus-Leppan H, Shankar R. Valproate and the Pregnancy Prevention Programme-exceptional circumstances. British Journal General Practice (2019) In press
  11. Cock HR Medicinal Cannabis: the role of medical cannabis in epilepsy. Epilepsy Professional (2018); 50:26-31
  12. Cock HR, Edwards MJ. Functional neurological disorders – acute presentations and management. Clinical Medicine (2018); 18:414-417 doi:10.7861/clinmedicine.18-5-414
  13. Angus-Leppan H, Shankar R, Cock HR. Valproate, women and exceptional circumstances. BMJ (2018); 362:k3625 doi: https://doi.org/10.1136/bmj.k3625
  14. Cock HR. Anticonvulsant drugs section in Chapter 13, Neurological Drugs, Oxford Desk Reference Critical Care. Waldmann C, Rhodes A, Soni N and Handy J (Eds), Oxford University In Press 2019
  15. Koepp M, Cock H, Lawden M, McClean B, McCorry D, Sieradzan K, Slaght S. Appropriate positioning of eslicarbazepine acetate in the treatment pathway for people with focal-onset seizures. Key Opinions in Medicine (2018); 2(1)
  16. Dobson R, Cock HR, Brex P, Giovannoni G. How to do it: Vitamin D supplementation. Practical Neurology (2018); 18:35-42 http://dx.doi.org/10.1136/practneurol-2017-001720
  17. Stienen MN, Schaller K, Cock H, Lisnic V, Regli L, Thomson N. eLearning resources to supplement postgraduate neurosurgery training. Acta neurochirgica (2017); 59(2):325-37 https://doi.org/10.1007/s00701-016-3042-7
  18. Vivekananda U, Cock H, Mula M. A case of de novo psychosis ten years following successful epilepsy surgery. Seizure (2016); 41:4-5
  19. *Galtrey CM, Mula M, Cock HR. Stress and epilepsy: fact or fiction and what should you do about it? Practical Neurology (2016) 16 (4): 270-278 DOI:10.1136/practneurol-2015-001337
  20. Nash P and Cock HR, Epilepsy on the Acute Medical Unit, Foundation Years Journal (2016) 10 (2); 14-18.
  21. Galizia EC, Mula M, Moynihan B, Khan U, Pereira A, Cock HR. The prognosis of acute symptomatic seizures after ischaemic stroke, JNNP Online First DOI:10.1136/jnnp-2015-311849
  22. Galtrey CM and Cock HR. Stress and epilepsy, Chapter 15 in Neuropsychiatric Symptoms of Epilepsy, edited by Dr. Marco Mula, Springer (2015)
  23. *Mantoan L, Cock HR. Future focal treatments for epilepsy. In Treatment of Epilepsy (4rd Edition), Eds Shorvon, Perucca, Engel, Blackwell Science UK (2015), Chapter 80, pp 987-998. DOI: 1002/9781118936979.ch80
  24. Vodusek DB, Cock HR and Boon P. The first congress of the European Academy of neurology. ACNR (2015) 15(4):25-25 http://www.acnr.co.uk/2015/09/the-first-congress-of-the-european-academy-of-neurology/
  25. *Cock HR. Drug induced Status epilepticus. Epilepsy and behaviour (2015) 49:76 – 82 DOI:1016/j.yebeh.2015.04.034
  26. *Mula M, Cock HR. More than seizures: improving the lives of people with refractory epilepsy. European J Neurology (2015) 22(1):24-30 DOI:1111/ene.12603
  27. Cock HR, Bone Health and Epilepsy. Epilepsy 2015. Edited by Edited by FJ Rugg-Gunn and JE Smalls, also available at http://www.epilepsysociety.org.uk/sites/default/files/attachments/Chapter40Cock.pdf
  28. Cock HR . The 4th London-Innsbruck Colloquium on status epilepticus and acute seizures. ACNR (2013) 13; 4: 29 http://www.acnr.co.uk/2013/08/the-4th-london-innsubruck-colloquium-on-status-epilepticus-and-acute-seizures/
  29. Cock HR, Bone Health and Epilepsy. Epilepsy 2013. Edited by Edited by FJ Rugg-Gunn and JE Smalls (2013)
  30. Cock H, (2012). Paul Habershon Scott OBITUARY. BRITISH MEDICAL JOURNAL, 344. DOI:1136/bmj.d8100
  31. Cock HR, Bone Health and Epilepsy. Epilepsy 2011. Edited by Edited by FJ Rugg-Gunn and JE Smalls (2011)
  32. Loszadi D A, Von Oertzen T, Cock HR. Epilepsy: Recent Advances. J Neurol (2010) 257 (11):1946-51 DOI: 1007/s00415-010-5740-z
  33. Shorvon S D, Tomson, T, Cock HR. The management of epilepsy during pregnancy – progress is painfully slow; Epilepsia (2009) 50(5):973-974 DOI:1111/j.1528-1167.2009.02134.x
  34. Cock H. Status epilepticus and the law courts. Epilepsia (2009) 50 (Suppl 12):73-74. Innsbruck International Colloquium on Status Epilepticus, Austria. DOI:1111/j.1528-1167.2009.02351.x
  35. Cock HR, Nilsen K E. Future focal treatments for epilepsy. In Treatment of Epilepsy (3rd Edition), Eds Shorvon, Perucca, Engel, Blackwell Science UK (2009) Chapter 84, pp 1043-1050 ISBN: 978-1-4443-1667-4
  36. Cock HR, Bone Health and Epilepsy. Epilepsy 2009, Eds Sander J W S, Walker M C, Smalls J E. Meritus Communications, Crowborough UK (2009)
  37. Cock HR, The role of mitochondria in status epilepticus, Epilepsia (2007), 48(suppl 8):24-27 DOI:1111/j.1528-1167.2007.01341.x
  38. Cock HR, Bone Health and Epilepsy. Epilepsy 2007, Eds Sander J W S, Walker M C, Smalls J E. Meritus Communications, Crowborough UK (2007)
  39. Walker M C, Cross H, Smith S, Young C, Aicardi J, Appleton R, Aylett S, Besag F, Cock HR, DeLorenzo R, Drislane F, Duncan J S, Ferrie C, Fujikawa D, Gray W P, Kaplan P, Koutroumandis M, O’Regan M, Plouin P, Sander J W A, Scott R, Shorvon S D, Treiman D, Wasterlain C, Wieshmann U. Nonconvulsive status epilepticus: Epilepsy Research Foundation Workshop Reports. Epileptic Disorders (2005) 7(3):253-96 http://www.ncbi.nlm.nih.gov/pubmed/16162436#
  40. Kelso A R C, Cock HR, Status epilepticus. Practical Neurology (2005) 5(6):322-333 DOI:1111/j.1474-7766.2005.00347.x
  41. Bigham S, Cock HR, Acute confusional states. British Journal of Hospital Medicine (2005) 66(8):8-11 http://www.ncbi.nlm.nih.gov/pubmed/16417113
  42. Kelso ARC, Cock HR, Advances in epilepsy. British Medical Bulletin (2005) 72(1):135-148 DOI:1093/bmb/ldh045
  43. Cock HR. Chapter 5, Mitochondrial dysfunction and oxidative stress in epilepsy. In: Focus on Epilepsy Research, Nova Science, New York (2005) pp105-138
  44. Cock HR, Bone Health and Epilepsy. Epilepsy 2005, Eds Sander J W S, Walker M C, Smalls J E. Meritus Communications, Crowborough UK (2005)
  45. Nilsen K E, Cock HR, Focal treatment for refractory epilepsy: hope for the future? Brain Res Reviews (2004) 44:141-153 DOI:1016/j.brainresrev.2003.11.003
  46. Nilsen K E, Cock HR. Chapter 74, Future focal surgical treatments for epilepsy. In Treatment of Epilepsy (2nd edition), Eds Shorvon, Fish, Dodson, Perucca. Blackwell Science, UK (2004) pp 925-933 ISBN: 978-0-632-06046-7
  47. Cock HR, Bone Health and Epilepsy. In : Epilepsy 2003, from synapse to society, Eds Sander J W S, Walker M C, Smalls J E. Meritus Communications, Crowborough UK (2003)
  48. Cock HR, Mitochondrial Diseases and Epilepsy, leading article, Epilepsy Monitor (2003) 7(3):pp 45-49
  49. Cock HR, Shorvon S D. Chapter 75, Status Epilepticus. In: Diseases of the Nervous System: Clinical neuroscience and therapeutic principles (3rd Edition), Eds. Asbury A K, McDonald W I, McArthur J C, McKhann G and Goadsby P, Cambridge University Press, UK. (2002) pp 1271-80 ISBN: 9780521793513
  50. Cock HR, The role of mitochondria and oxidative stress in neuronal damage following brief and prolonged seizures. Progress in Brain Research (2002) 135(16):187-96 DOI:1016/S0079-6123(02)35018-0
  51. Humphrey P, Bateman D, Bracewell M, Cock H, Compston A, Nichols P, Thrush D, Venables G, Wroe S, Saunders J, Stevens DL. Acute neurological emergencies in adults; Report, Association of British Neurologists (2002)
  52. Cock HR, Schapira A H V. Mitochondrial myopathies. In: Twentieth Century Neurology – The British Contribution. Ed. Clifford Rose F. Imperial College Press, London (2002) pp 255 – 282. ISBN: 978-1-86094-245-7
  53. Cock HR, Shorvon S D. The spectrum of movement disorders in epilepsia partialis continua. In: Epilepsy and Movement Disorders, Eds. Guerrini R, Aicardi J, Andermann. Cambridge University Press, UK (2002) pp 211-226 DOI: 1017/CBO9780511629419.014
  54. Cock HR. Epilepsy on the net. JNNP (2001) 70(suppl): 8
  55. Cock HR, Schapira A H V. Mitochondrial DNA mutations and mitochondrial dysfunction in Epilepsy Epilepsia (1999) 40:33-40 DOI: 1111/j.1528-1157.1999.tb00897.x
  56. Cock HR, Taanman J-W, Schapira A H V. Chapter 25:Mitochondrial DNA mutations and nuclear mitochondrial interactions in human disease. In: Papa S, Guerrieri F, Tager J (eds), Frontiers of Cellular Bioenergetics: molecular biology, biochemistry and physiopathology. Plenum Press, London. (1999) pp635 – 663 ISBN-10: 0306458519
  57. Schapira A H V, Cock HR. Mitochondrial myopathies and encephalopmyopathyies European Journal of Clinical Investigation (1999) 29:886-898 DOI: 10.1046/j.1365-2362.1999.00540.x
  58. Cock HR, Duncan J S. Generic prescribing in epilepsy: is it worth it? Costs and Options (2000) 20:20-22.
  59. Cock HR, Duncan J. Generic prescribing of AEDs: equivalent or not? In: Todd D (Ed), National Association of Primary Care, Official Review; Scorpio Publishing, London (1999) pp229-233

Professor Cock was one of the first UK neurologists to undertake a professional qualification in teaching (2001, Institute of Education), is a Fellow of the Higher Education Academy, a GMC recognized trainer, and a Member of the Association of Medical Education in Europe. She has held a range of roles locally and internationally, and actively participated in all aspects of education and learner support in higher and post-graduate education, including PhD supervision and Examination.  Having been appointed as a Senior Lecturer in 2003, she was  promoted to Reader in 2011, and Professor in 2016. She welcomes enquires from SGUL staff interested in finding out about her various roles and career progression. 

Roles: Local 

  • Course Director for Medicine (MBBS), 2019 -
  • Information Governance Lead, Institute of Medical and Biomedical Education 2018 - 
  • Co-Section head, Clincal teachers, 2018 - 
  • MBBS Penultimate year NeuroPlus Placement lead 2009 - 2019
  • MBBS Career Development Tutor 2011 - 2014
  • MBBS 4Y1 and T year Life Control (Neurology/psychiatry) co-module lead, 2003-2018 
  • BSc Biomedical Science, Clinical Neurosciences Epilepsy lead 2005-2019
  • Led a Disability theme revew and introduced rehabilitation multi-professional component to the curriculum in 2009.    
  • Personal tutor (MBBS) 2003 - 

National and UK external

  • UK Epilepsy Masterclass Faculty, 2002 - 
  • Epilepsy Society Specialist Registrar Training weekends Faculty, 2002
  • External Subject Expert, internal quality review post-graduate neurosicences courses, University College London, 2018
  • External examiner, Clinical Neurosciences MSc University College London, 2009-2012

International

  • International league Against Epilepsy, e-learning task force 2018 - 20, includign author contributions to an online curriculum for post-graduate epilepsy education. 
  • Chair of the Education Committee, Board Member European Academy of Neurology, 2014-2018. This role included responsibility for the delivery and quality assurance of fellowships, departmental exchanges, teaching courses and continuing medical education for neurology trainees and consultants across Europe.
  • Teaching Course Director, European Neurological Society 2012-2014
  • Clinical Lead at ebrain, 2009-2019, a not for profit clinical neuroscience e-learning platform with over 600 sessions, webinars and self-assessment exercises. 
Find a profileSearch by A-Z